Cancers最新文献

{"title":"Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer.","authors":"Stefan Lukac, Visnja Fink, Davut Dayan, Brigitte Rack, Wolfgang Janni, Krisztian Lato, Kristina Veselinovic, Sabine Heublein, Thomas Wolfram Paul Friedl, Elena Leinert","doi":"10.3390/cancers17091498","DOIUrl":"10.3390/cancers17091498","url":null,"abstract":"<p><strong>Background: </strong>The anti-tumor response of the immune system is pivotal for treating triple-negative breast cancer (TNBC), particularly as targeted therapies are limited. However, the impact of immune-modulating factors such as the application of granulocyte-stimulating factors (G-CSFs) or infections, including febrile neutropenia, prophylactic or therapeutical application of oral antibiotics (OABs), and the need for intravenous antibiotics (IABs), on survival outcomes remains unclear.</p><p><strong>Methods: </strong>1583 patients with early-stage TNBC enrolled in the SUCCESS A or C study underwent primary surgery, adjuvant chemotherapy, and radiotherapy if indicated. All patients had Eastern Cooperative Oncology Group (ECOG) status ≤ 2. The effects of G-CSF, OAB, and IAB application on overall survival (OS), invasive disease-free survival (iDFS), breast cancer-specific survival (BCSS), and distant disease-free survival (DDFS) were assessed.</p><p><strong>Results: </strong>Only IAB treatment was significantly associated with decreased survival in univariable analyses (OS: <i>p</i> = 0.003; iDFS: <i>p</i> = 0.036; BCSS: <i>p</i> = 0.011; DDFS: <i>p</i> = 0.044), while G-CSF and OAB administration were not. Adjusted multivariable Cox regressions including febrile neutropenia and dose reduction/shift, ECOG, age of patients, and other clinicopathological parameters confirmed a significant negative effect of IABs on OS (<i>p</i> = 0.020), BCSS (<i>p</i> = 0.018), and DDFS (<i>p</i> = 0.044).</p><p><strong>Conclusions: </strong>In summary, IABs during adjuvant chemotherapy seems to be a risk factor for inferior OS, BCSS, and DDFS in TNBC patients, possibly by affecting microbiome-related immune response modulation. Hence, preventive measures to avoid the need for IABs should be considered in these patients.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locoregional and Surgical Treatment of Single-Nodule Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and a Meta-Analysis.","authors":"Marco Maria Pascale, Camilla Marandola, Francesco Frongillo, Erida Nure, Salvatore Agnes","doi":"10.3390/cancers17091501","DOIUrl":"10.3390/cancers17091501","url":null,"abstract":"<p><p><b>Background:</b> Liver transplantation (LT) is regarded as a curative approach for patients with hepatocellular carcinoma (HCC), especially those with underlying advanced liver disease. However, the recurrence of HCC post-LT poses significant challenges, with reported rates of 15-20% within the first two years following surgery. Effective management of single-nodule recurrence is critical to improving patient outcomes. <b>Methods:</b> This meta-analysis evaluates the efficacy of surgical resection versus locoregional therapies (LRT) in patients with localized HCC recurrence after LT. We adhered to the PRISMA Statement in conducting a thorough search of relevant studies published from 2009 to 2024, ultimately including ten studies that met our eligibility criteria. <b>Results:</b> The results indicate that patients undergoing surgical treatment displayed superior one-year overall survival (OS) rates compared to those receiving LRT (71% vs. 62%, <i>p</i> = 0.038), as well as higher one-year disease-free survival (DFS) rates (60% vs. 54%, <i>p</i> = 0.042). Notably, patients in the LRT group presented with more advanced HCC characteristics prior to transplantation, including higher rates of microvascular invasion and elevated alpha-fetoprotein levels. <b>Conclusions:</b> Our findings suggest that while surgical resection is associated with better survival outcomes, the choice between surgical and locoregional approaches must be individualized based on tumor characteristics and liver function. The ongoing development of standardized guidelines with the inclusion of immunotherapy or targeted agents will be essential in refining treatment pathways and improving outcomes for patients experiencing HCC recurrence following LT.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Café-Au-Lait Macules in Neurofibromatosis Type 1: Birthmark or Biomarker?","authors":"Andrea Santangelo, Cristina Chelleri, Marco Tomasino, Mattia Pasquinucci, Francesca Cappozzo, Pasquale Striano, Maria Cristina Diana, Marcello Scala","doi":"10.3390/cancers17091490","DOIUrl":"10.3390/cancers17091490","url":null,"abstract":"<p><strong>Background: </strong>Neurofibromatosis type 1 (NF1) is a rare multisystem disorder characterized by variable expressivity and increased tumor risk. Café-au-lait macules (CALMs) are a hallmark of the disease, often representing one of the earliest clinical manifestations and allowing a clinical NF1 diagnosis if six or more are present. In this study, we aimed to investigate the prognostic value of CALMs at birth in NF1 patients.</p><p><strong>Methods: </strong>We conducted a retrospective study in patients aged ≥ 4 years presenting with CALMs at our Institution between 2020 and 2021, with a minimum follow-up of four years. We retrospectively collected data on CALMs at birth and other clinical manifestations associated with NF1.</p><p><strong>Results: </strong>Among 208 patients evaluated, including 147 with a confirmed diagnosis of NF1, 110 did not show CALMs at birth, and 98 had at least one. The absence of CALMs at birth did not correlate with a lower likelihood of NF1. In contrast, the CALM number at birth directly correlated with the likelihood of NF1, up to 95% in patients with ≥5 macules. Additionally, a higher number of CALMs correlated with a greater prevalence of plexiform neurofibromas (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Our findings suggest that a higher number of CALMs may indicate a more severe form of NF1, with an increased risk of plexiform neurofibromas. These results emphasize the importance of a comprehensive evaluation of patients with CALMs, especially in case of multiple lesions, aiming at implementing early NF1 diagnosis, follow-up strategies, and overall patient management.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model.","authors":"Hui Li, Morteza Salehjahromi, Myrna C B Godoy, Kang Qin, Courtney M Plummer, Zheng Zhang, Lingzhi Hong, Simon Heeke, Xiuning Le, Natalie Vokes, Bingnan Zhang, Haniel A Araujo, Mehmet Altan, Carol C Wu, Mara B Antonoff, Edwin J Ostrin, Don L Gibbons, John V Heymach, J Jack Lee, David E Gerber, Jia Wu, Jianjun Zhang","doi":"10.3390/cancers17091499","DOIUrl":"10.3390/cancers17091499","url":null,"abstract":"<p><strong>Background/objectives: </strong>Persistent pulmonary nodules are at higher risk of developing into lung cancers. Assessing their future cancer risk is essential for successful interception. We evaluated the performance of two risk prediction models for persistent nodules in hospital-based cohorts: the Brock model, based on clinical and radiological characteristics, and the Sybil model, a novel deep learning model for lung cancer risk prediction.</p><p><strong>Methods: </strong>Patients with persistent pulmonary nodules-defined as nodules detected on at least two computed tomography (CT) scans, three months apart, without evidence of shrinkage-were included in the retrospective (<i>n</i> = 130) and prospective (<i>n</i> = 301) cohorts. We analyzed the correlations between demographic factors, nodule characteristics, and Brock scores and assessed the performance of both models. We also built machine learning models to refine the risk assessment for our cohort.</p><p><strong>Results: </strong>In the retrospective cohort, Brock scores ranged from 0% to 85.82%. In the prospective cohort, 62 of 301 patients were diagnosed with lung cancer, displaying higher median Brock scores than those without lung cancer diagnosis (18.65% vs. 4.95%, <i>p</i> < 0.001). Family history, nodule size ≥10 mm, part-solid nodule types, and spiculation were associated with the risks of lung cancer. The Brock model had an AUC of 0.679, and Sybil's AUC was 0.678. We tested five machine learning models, and the logistic regression model achieved the highest AUC at 0.729.</p><p><strong>Conclusions: </strong>For patients with persistent pulmonary nodules in real-world cancer hospital-based cohorts, both the Brock and Sybil models had values and limitations for lung cancer risk prediction. Optimizing predictive models in this population is crucial for improving early lung cancer detection and interception.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safely Targeting Cancer, the Wound That Never Heals, Utilizing CBP/Beta-Catenin Antagonists.","authors":"Yusuke Higuchi, Jia-Ling Teo, Daniel Yi, Michael Kahn","doi":"10.3390/cancers17091503","DOIUrl":"10.3390/cancers17091503","url":null,"abstract":"<p><p>Stem cells, both normal somatic (SSC) and cancer stem cells (CSC) exist in minimally two states, i.e., quiescent and activated. Regulation of these two states, including their reliance on different metabolic processes, i.e., FAO and glycolysis in quiescent versus activated stem cells respectively, involves the analysis of a complex array of factors (nutrient and oxygen levels, adhesion molecules, cytokines, etc.) to initiate the epigenetic changes to either depart or enter quiescence. Quiescence is a critical feature of SSC that is required to maintain the genomic integrity of the stem cell pool, particularly in long lived complex organisms. Quiescence in CSC, whether they are derived from mutations arising in SSC, aberrant microenvironmental regulation, or via dedifferentiation of more committed progenitors, is a critical component of therapy resistance and disease latency and relapse. At the beginning of vertebrate evolution, approximately 450 million years ago, a gene duplication generated the two members of the Kat3 family, CREBBP (CBP) and EP300 (p300). Despite their very high degree of homology, these two Kat3 coactivators play critical and non-redundant roles at enhancers and super-enhancers via acetylation of H3K27, thereby controlling stem cell quiescence versus activation and the cells metabolic requirements. In this review/perspective, we discuss the unique regulatory roles of CBP and p300 and how specifically targeting the CBP/β-catenin interaction utilizing small molecule antagonists, can correct lineage infidelity and safely eliminate quiescent CSC.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression Characteristics of 3-Marker Panel (PAX2, PTEN, and β-Catenin) in Benign Interval and Secretory Endometrium and Secretory Endometrial Precancer.","authors":"Shuang Niu, Kyle Molberg, Jackson Chen, Lesley Conrad, Elena Lucas, Hao Chen","doi":"10.3390/cancers17091495","DOIUrl":"10.3390/cancers17091495","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Despite advancements in treatment options, endometrial cancer remains a significant threat to women, underscoring the importance of early detection of atypical hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN), the widely accepted histological precursor to endometrial carcinoma. Even with refinements in morphological criteria for the diagnosis of AH/EIN, accurate diagnosis remains challenging for pathologists, particularly in cases with secretory changes. Morphological alterations resulting from secretory-related changes further complicate the application of diagnostic criteria, emphasizing the need for reliable biomarkers. Previous studies have demonstrated that a panel consisting of three immunohistochemical markers, PAX2, PTEN, and β-catenin, can be effectively utilized for the identification of AH/EIN in various non-secretory scenarios. <b>Methods</b>: In this study, a total of 69 AH/EIN within secretory endometrium were analyzed using this panel. Benign interval endometrium (<i>n</i> = 57) and secretory phase endometrium (<i>n</i> = 71) were also analyzed for PAX2, PTEN, and β-catenin expression as controls. <b>Results</b>: The 3-marker panel successfully identified 93% of secretory AH/EIN, comparable to its performance in identifying non-secretory bona fide AH/EIN (92.8%) and AH/EIN within endometrial polyps (92.4%). Of note, β-catenin expression in benign interval endometrium commonly displayed weak nuclear staining (67%), which could pose a diagnostic pitfall when using the 3-marker panel. Overall, the results demonstrate the diagnostic utility of the 3-marker panel in clinical practice in identifying AH/EIN within challenging secretory phase endometrium cases. <b>Conclusions</b>: Combined with previous research highlighting its effectiveness in other challenging contexts-such as AH/EIN in polyps, small-sized EIN (subdiagnostic EIN), and progestin-treated EIN-this study provides strong evidence supporting the panel's broad applicability in resolving major diagnostic challenges related to the precise diagnosis of AH/EIN.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Epstein-Barr Virus Infection and PD-L1 Expression in Gastric Cancer: Prevalence, Clinicopathological Features, and Prognostic Implications.","authors":"Jirapat Wonglhow, Jarukit Tantipisit, Panu Wetwittayakhlang, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Kanet Kanjanapradit, Phatcharaporn Thongwatchara, Arunee Dechaphunkul","doi":"10.3390/cancers17091492","DOIUrl":"10.3390/cancers17091492","url":null,"abstract":"<p><strong>Background: </strong>Epstein-Barr virus-associated gastric cancer (EBVaGC) represents a distinct molecular subgroup with potential responsiveness to immunotherapy approved for programmed death-ligand 1 (PD-L1)-positive gastric cancer. This retrospective study aimed to assess the prevalence and association between EBVaGC and PD-L1 positivity among patients with gastric adenocarcinoma treated at a university hospital in Southern Thailand from January 2017 to October 2023.</p><p><strong>Methods: </strong>The EBV status of the patients and PD-L1 expression were determined using in situ hybridization and immunohistochemistry, respectively.</p><p><strong>Results: </strong>The prevalence of EBVaGC was 4.5% among 132 patients, whereas 9.1% of patients exhibited a PD-L1 combined positive score (CPS) of ≥1, with no significant association observed between them. EBVaGC was more prevalent in males, non-antral tumors, diffuse/mixed histologic subtypes, and poorly differentiated tumors. Median overall survival for patients with EBVaGC and PD-L1 CPS ≥ 1 was 9.48 and 14.19 months, respectively, compared with 10.32 and 9.79 months for those with non-EBVaGC (hazard ratio: 1.24; 95% CI: 0.50-3.04; <i>p</i> = 0.645) and PD-L1 CPS < 1 (hazard ratio: 0.82; 95% CI: 0.40-1.69; <i>p</i> = 0.590), respectively.</p><p><strong>Conclusions: </strong>Our findings revealed a low prevalence of EBVaGC and PD-L1 positivity in Thailand, with no significant association or survival impact observed. These findings highlight the regional variation in these biomarkers and support EBV as an independent biomarker from PD-L1. However, further research, particularly studies evaluating immunotherapy outcomes, is warranted to clarify the predictive and clinical significance of EBV in gastric cancer.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival.","authors":"Jie Shen, Yufan Guan, Supraja Gururaj, Kai Zhang, Qian Song, Xin Liu, Harry D Bear, Bernard F Fuemmeler, Roger T Anderson, Hua Zhao","doi":"10.3390/cancers17091502","DOIUrl":"10.3390/cancers17091502","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer disparities persist globally, with growing evidence implicating neighborhood and built environmental factors in disease outcomes.</p><p><strong>Methods: </strong>This study investigates the associations between neighborhood disadvantage, environmental exposures, and breast tumor characteristics and survival among 3041 stage I-III breast cancer patients treated at the University of Virginia Comprehensive Cancer Center (2014-2024). Neighborhood disadvantage was assessed via the Area Deprivation Index (ADI), while environmental exposures included PM2.5, green space (NDVI), and food indices (modified retail food environment index (mRFEI), retail food activity index (RFAI)). Multivariable regression and Cox models adjusted for demographic, socioeconomic, and clinical covariates were employed.</p><p><strong>Results: </strong>A higher ADI score was associated with aggressive tumor characteristics, including advanced stage (Odds Ratio (OR) = 1.06, 95% Confidence Interval (CI):1.01-1.11), poor differentiation (OR = 1.07, 1.01-1.15), ER-negative status (OR = 1.06, 1.01-1.12), and triple-negative breast cancer (TNBC) (OR = 1.08, 1.02-1.16), as well as younger diagnosis age (β = -0.22, -0.36 to -0.09). PM2.5 exposure was correlated with advanced tumor stage (OR = 1.24, 1.09-1.40 for stage III) but paradoxically predicted improved survival (Hazard Ratio (HR) = 0.71, 0.63-0.82). The food environment indices showed subtype-specific survival benefits: higher mRFEI and RFAI scores were linked to reduced mortality in ER-negative (HR = 0.45, 0.23-0.85 and HR = 0.61, 0.38-0.97) and TNBC (HR = 0.40, 0.18-0.90 and HR = 0.48, 0.26-0.87) patients. NDVI scores exhibited no significant associations.</p><p><strong>Conclusion: </strong>Our findings underscore the dual role of neighborhood disadvantage and the built environmental in breast cancer outcomes. While neighborhood disadvantage and PM2.5 exposure elevate tumor aggressiveness, survival disparities may be mediated by other factors. Improved food environments may enhance survival in aggressive subtypes, highlighting the need for integrated interventions addressing socioeconomic inequities, environmental risks, and nutritional support needs.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Super</i>-Superselective Level VB Neck Dissection for Papillary Thyroid Cancer.","authors":"Dana M Hartl, Davide Lombardi, Ricard Simo, Radu Mihai, Aleix Rovira, Enyi Ofo, Iain J Nixon","doi":"10.3390/cancers17091497","DOIUrl":"10.3390/cancers17091497","url":null,"abstract":"<p><strong>Objective: </strong>Therapeutic lateral neck dissection is recommended for papillary thyroid cancer with metastatic lymph nodes detected on palpation or on preoperative imaging. Current guidelines recommend systematic dissection of levels IIA, III, IV and VB in these patients. Despite this recommendation, management of level V remains controversial due to a varying degree of clinical and occult lymph node involvement reported in published retrospective studies, but also due to the functional risk involved in level V dissection in which the spinal accessory nerve may be temporarily or permanently injured. The aim of this review was to address the issues involved in level VB dissection and to provide our view of surgical management of level VB.</p><p><strong>Method: </strong>Narrrative review.</p><p><strong>Result: </strong>We propose a new concept of a partial or \"<i>super</i>-superselective\" level VB dissection in patients with clinical disease in levels IIA, III and IV.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of p53 in Endometrial Carcinoma Biopsy and Corresponding Hysterectomy Cases in a Real-World Setting: Which Cases Need Molecular Work-Up?","authors":"Marie-Lisa Eich, Janna Siemanowsk-Hrach, Uta Drebber, Nicolaus Friedrichs, Peter Mallmann, Christian Domröse, Dominik Ratiu, Sabine Merkelbach-Bruse, Reinhard Büttner, Alexander Quaas, Birgid Schömig-Markiefka","doi":"10.3390/cancers17091506","DOIUrl":"10.3390/cancers17091506","url":null,"abstract":"<p><p>Over 420,242 women were diagnosed with uterine cancer worldwide in 2022 [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 9","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12071035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}